Cybin Past Earnings Performance
Past criteria checks 0/6
Cybin's earnings have been declining at an average annual rate of -29.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually.
Key information
-29.35%
Earnings growth rate
24.23%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | n/a |
| Return on equity | -70.72% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2026 |
Recent past performance updates
Recent updates
HELP: Phase 3 Depression Data And Supportive Policy Tailwinds Will Drive Psychedelic Therapy Demand
Analysts have roughly doubled their fair value estimate for Cybin to about $15.37 per share from about $7.78. They attribute this change to higher assumed revenue growth, improved profit margins and the expectation of a very large future P/E multiple for the psychedelic neuropsych sector, based on recent sector research and regulatory signals.Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
Summary Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004 (IM DMT) data suggest efficacy and durability when used as adjunctive therapies, although this comes from small trials. Helus is conducting a phase III trial for HLP003, which could validate its clinical profile and reduce the valuation discount relative to peers. Despite substantial clinical and commercialization risks, the existence of established psychedelic infrastructure and the unmet need in the market, along with Helus’ modest valuation, create an attractive risk-reward opportunity. Read the full article on Seeking Alpha
HELP: Phase 3 Depression Data And New CEO Appointment Will Drive Repricing
Analysts lifted their fair value estimate for Cybin from $37.57 to $41.62 per share, citing higher projected revenue growth and slightly stronger profit margins supported by growing confidence in regulatory trends and sector readthroughs from recent psychedelic neuropsych research coverage. Analyst Commentary Recent sector research gives investors additional context for how Cybin might be viewed alongside other psychedelic neuropsychiatry companies.HELP: Phase 3 Depression Readout And Cash Raise Will Drive Repricing
Analysts have reduced their price target on Cybin to reflect a lower fair value estimate of about $37.57. This adjustment is offset by expectations for very large future revenue growth, supported by a reduced future P/E assumption and only modest changes to profit margin and discount rate inputs.
HELP: Sector Depression Trial Milestones Will Shape This Psychedelic Undervaluation View
Analysts have reduced their price target for Cybin to reflect a revised fair value estimate of about $70.05, citing updated views on long term revenue potential, profit margins, and an adjusted future P/E outlook informed by recent psychedelic sector research on comparable late stage drug developers. Analyst Commentary Recent sector research on late stage psychedelic drug developers is shaping how bullish analysts think about Cybin, especially when they compare it with peers working on deuterated psilocin and similar compounds.HELP: Policy Momentum On PTSD Treatments Will Drive Future Psychedelic Therapy Demand
Analysts have lowered their Cybin price targets to around $7.78 from about $22.14, citing updated assumptions that include a somewhat higher discount rate, slightly softer long term profit margins, and a reduced but still very large future P/E multiple, partly offset by higher projected revenue growth. What’s in the News for Cybin Cybin completed a follow on equity offering of approximately $50.0 million, issuing 10,309,280 common shares at a price of $4.85 per share, with a stated discount of $0.291 per security.We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?Revenue & Expenses Breakdown
How Cybin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 26 | 0 | -171 | 65 | 102 |
| 31 Mar 26 | 0 | -148 | 56 | 87 |
| 31 Dec 25 | 0 | -123 | 47 | 72 |
| 30 Sep 25 | 0 | -87 | 38 | 61 |
| 30 Jun 25 | 0 | -95 | 65 | 48 |
| 31 Mar 25 | 0 | -82 | 64 | 39 |
| 31 Dec 24 | 0 | -75 | 63 | 34 |
| 30 Sep 24 | 0 | -91 | 69 | 27 |
| 30 Jun 24 | 0 | -57 | 38 | 25 |
| 31 Mar 24 | 0 | -58 | 34 | 24 |
| 31 Dec 23 | 0 | -53 | 29 | 22 |
| 30 Sep 23 | 0 | -37 | 18 | 20 |
| 30 Jun 23 | 0 | -37 | 19 | 19 |
| 31 Mar 23 | 0 | -35 | 19 | 19 |
| 31 Dec 22 | 0 | -38 | 23 | 17 |
| 30 Sep 22 | 0 | -42 | 26 | 16 |
| 30 Jun 22 | 0 | -51 | 33 | 16 |
| 31 Mar 22 | 0 | -54 | 37 | 14 |
| 31 Dec 21 | 0 | -50 | 37 | 10 |
| 30 Sep 21 | 0 | -45 | 36 | 7 |
| 30 Jun 21 | 0 | -34 | 28 | 4 |
| 31 Mar 21 | 1 | -26 | 22 | 3 |
Quality Earnings: HELP is currently unprofitable.
Growing Profit Margin: HELP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HELP is unprofitable, and losses have increased over the past 5 years at a rate of 29.3% per year.
Accelerating Growth: Unable to compare HELP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HELP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1%).
Return on Equity
High ROE: HELP has a negative Return on Equity (-70.72%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 22:43 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cybin Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |